The epidermal growth factor receptor (EGFR) gene is frequently ampli®ed and rearranged in malignant gliomas with expression of oncogenic deletion mutants (DM). The most common mutant EGFRvIII, which contains a deletion of exons 2 ± 7, is constitutively autophosphorylated and ineciently downregulated. Other less common EGFR mRNA species in gliomas contain tandem duplication of exons, which encode the tyrosine kinase (TK) and calcium mediated receptor internalization (CAIN) domains of the molecule. We examined a panel of human malignant gliomas and found one tumor that expressed four related EGFR proteins, including 125-, 140-, 170-, and 180-kDa species. This tumor also contained four EGFR-related mRNA species, including both wild type EGFR and EGFRvIII transcripts. A third transcript contained a deletion of exons 2 ± 7 and 12 ± 13 corresponding to the 125-kDa protein. A fourth transcript contained an in-frame, tandem duplication of exons 2 ± 7 (EGFR.TDM/2 ± 7). The 180-kDa, tandem duplication mutant (TDM) exhibited enhanced basal phosphorylation and impaired downregulation. In contrast to the 140-kDa EGFRvIII; however, phosphorylation of the 180-kDa EGFR.TDM/2 ± 7 was strongly induced by ligand. Expression of both deletion and tandem duplication mutants in the same tumor suggests that the mechanisms responsible for DM and TDM formation might be closely related. Oncogene (2000) 19, 4542 ± 4548.
The epidermal growth factor receptor (EGFR) gene is frequently ampli®ed and rearranged in malignant gliomas with expression of oncogenic deletion mutants (DM). The most common mutant EGFRvIII, which contains a deletion of exons 2 ± 7, is constitutively autophosphorylated and ineciently downregulated. Other less common EGFR mRNA species in gliomas contain tandem duplication of exons, which encode the tyrosine kinase (TK) and calcium mediated receptor internalization (CAIN) domains of the molecule. We examined a panel of human malignant gliomas and found one tumor that expressed four related EGFR proteins, including 125-, 140-, 170-, and 180-kDa species. This tumor also contained four EGFR-related mRNA species, including both wild type EGFR and EGFRvIII transcripts. A third transcript contained a deletion of exons 2 ± 7 and 12 ± 13 corresponding to the 125-kDa protein. A fourth transcript contained an in-frame, tandem duplication of exons 2 ± 7 (EGFR.TDM/2 ± 7). The 180-kDa, tandem duplication mutant (TDM) exhibited enhanced basal phosphorylation and impaired downregulation. In contrast to the 140-kDa EGFRvIII; however, phosphorylation of the 180-kDa EGFR.TDM/2 ± 7 was strongly induced by ligand. Expression of both deletion and tandem duplication mutants in the same tumor suggests that the mechanisms responsible for DM and TDM formation might be closely related. Oncogene (2000) 19, 4542 ± 4548.
Keywords: epidermal growth factor receptor; EGFRvIII; glioma; oncogene; recombination; V(D)J High-level expression of the epidermal growth factor receptor (EGFR) produces ligand-dependent cellular transformation of immortalized astrocytes (Frisa et al., 1996) . In addition, EGFR has been implicated in the development of malignant astrocytomas (gliomas), in which co-expression of EGFR and activating ligand is associated with stimulation of cellular proliferation via an autocrine mechanism. EGFR gene ampli®cation and rearrangement are present in a high percentage of malignant gliomas (Libermann et al., 1985; Humphrey et al., 1988; Bigner et al., 1990; Wong et al., 1987; Ekstrand et al., 1991) . Gene rearrangement is associated with the simultaneous expression of wild type and oncogenic deletion mutant receptors. Thus, in addition to autocrine stimulation of the wild type EGFR, deletion mutants appear to play a role in the development of malignant gliomas
The most common EGFR mutant in malignant gliomas is EGFRvIII, a 140-kDa molecule containing an in-frame deletion of amino acids 6 ± 273. EGFRvIII is encoded by a transcript with deletion of exons 2 ± 7 (Sugawa et al., 1990; Humphrey et al., 1991; Wong et al., 1992) . It is unclear whether this results from dierential transcript splicing or intragenic recombination between¯anking introns 1 and 7 (Sugawa et al., 1990) . Nevertheless, this deletion mutation leads to the loss of a portion of domain I, and all of domain II in the extracellular region of the molecule. Mutant EGFR such as EGFRvIII may promote oncogenesis by way of one or more mechanisms, including: impaired receptor downregulation, stimulation of dierent signaling pathways than the wild type receptor, abrogation of apoptotic mechanisms, and constitutive autophosphorylation (Nishikawa et al., 1994; Nagane et al., 1996; Huang et al., 1997; Chu et al., 1997) . EGFRvIII is capable of oncogenic transformation in the absence of ligand and its expression may suggest tumor aggressiveness and resistance to chemotherapy (Nishikawa et al., 1994; Schlegel et al., 1994; Batra et al., 1995; Nagane et al., 1998) .
In addition to deletion of EGFR exons, two mutants with tandem duplication of portions of the intracellular region of the EGFR gene have been reported in glioma cell lines and biopsy specimens. One EGFR mutant contains a tandem duplication of exons 18 ± 26, which encode the tyrosine kinase (TK) and calcium internalization (CAIN) domains of the molecule (Fenstermaker et al., 1998) . Another mutant contains a tandem duplication of exons 18 ± 25 with duplication of the entire TK region and a portion of the CAIN domain (Ciesielski and Fenstermaker, 2000; Frederick et al., 2000) . Along with data presented here regarding tandem duplication of exons 2 ± 7, evidence suggests the existence of a distinct class of EGFR mutants present in some human gliomas. The molecular processes leading to the development of deletion and tandem duplication mutations in EGFR may be fundamentally related, however, involving recombination between susceptible introns.
EGFR-related proteins larger than the 170-kDa wild type receptor have been observed previously in human glioma cell lines and tumors (Steck et al., 1988; Panneerselvam et al., 1995) . We have identi®ed a 190-kDa EGFR species in A-172 glioma cells and glioma biopsy samples and a 185-kDa form in KE and A-1235 human glioma cells. Both large EGFR forms result from tandem duplication of sequences within the intracellular region of the molecule (Fenstermaker et al., 1998; Ciesielski and Fenstermaker, 2000) . In the current study, we examined EGFR-reactive forms in a series of human malignant glioma samples obtained at surgery (Figure 1 ). Two major EGFR species were identi®ed in most glioma samples including both 170-kDa and 140-kDa species. In addition to these two common EGFR forms, one tumor in this panel (RPG-28) contained 180-kDa and 125-kDa EGFR proteins expressed at high levels.
We used seven sets of EGFR-speci®c oligodeoxyribonucleotide (ODN) pairs in reverse transcriptionpolymerase chain reactions (RT ± PCR) to characterize EGFR-related transcripts expressed in RPG-28 ( Figure  2) . RNA from the A-431 carcinoma cell line containing the wild type 170-kDa EGFR protein species by itself was used as a control. Each ODN pair produced a single fragment with cDNA templates derived from control RNA (Ullrich et al., 1984) . Similarly, cDNA templates from RPG-28 produced fragments of identical size to that obtained with A-431 cDNA, indicating the presence of wild type EGFR transcripts in that tumor (Figure 2a ± e) . In addition, other major bands were noted in RPG-28.
First, we excluded the possibility of structural alteration in the intracellular portion of the EGFR transcripts from RPG-28, similar to those present in the TK/CAIN tandem duplication mutants, by using a speci®c RT ± PCR reaction as described previously (Figure 2a ; Ciesielski and Fenstermaker, 2000) . In addition to the PCR fragments containing wild type EGFR sequence, RPG-28 cDNA templates produced a number of fragments with ODN pairs binding to the extracellular region of the molecule. An ODN pair binding at +187 and +311 produced a second major fragment of 925-bp using cDNA from RPG-28 ( Figure  2b ODN binding at +1029 and +1113 produced a single major secondary band of 885 bp ( Figure 2c ). ODN binding at +187 and +1113 produced two major secondary bands; one larger (1727 bp), and the other smaller (125 bp) than the wild type EGFR band ( Figure 2d ). ODN binding at +187 and +3819 produced DNA fragments of 2489, 2831, 3632 and 4433 bp, which correspond to the complete coding region of each transcript (Figure 2e ). These data are consistent with the presence of four separate EGFRlike mRNA in RPG-28. Three of these transcripts dier from the wild type EGFR with speci®c alterations in the extracellular portion of each. No secondary bands were produced with cDNA from A431 cells.
PCR fragments from the various reactions were cloned into a plasmid for sequencing. This revealed that fragments from RPG-28 of wild type size all contained the exact nucleotide sequence of the wild type EGFR cDNA (Ullrich et al., 1984) . Sequence analysis of secondary major fragments from the various reactions revealed both deletion mutant (DM) and tandem duplication mutant (TDM) transcripts ( Figure 3 ). All EGFR mutations contained alterations in the cDNA sequence with either loss, or tandem duplication of speci®c exon groups resulting in the production of in-frame mutations.
Collectively, sequence data indicate the existence of four separate EGFR mRNA species in RPG-28 including a wild type EGFR transcript. A 2831-bp transcript contained a deletion of nucleotides +427 to +1075 corresponding to a loss of exons 2 ± 7, as has been reported for EGFRvIII (Ullrich et al., 1984; Callaghan et al., 1993) . The EGFRvIII transcript encodes a protein lacking the cysteine-rich domain II and a portion of domain I. A 2489-bp mRNA species contained a deletion of two separate groups of nucleotides including those from +427 to +1075, as in EGFRvIII, as well as those from +1485 to +1827. These deletions correspond to a loss of exons 2 ± 7 and exons 12 ± 13, respectively (Ullrich et al., 1984; Callaghan et al., 1993) . The size of this double-deletion transcript is compatible with that which is required to encode the 125-kDa, EGFRvIII/D12 ± 13 protein.
Hence, in addition to loss of domain II, EGFRvIII/ D12 ± 13 has lost a portion of domain III. In contrast to the deletion mutations, a fourth transcript in RPG-28 measuring 4433-bp in size contained in-frame, tandem copies of exons 2 ± 7. This transcript corresponds in size to that which would be required to encode the 180-kDa EGFR protein species shown in Figure 1 . The TDM transcript encodes an additional cysteine-rich domain II and a partial duplication of domain I.
Due to the loss of exons 2 ± 7, both EGFRvIII and EGFRvIII/D12 ± 13 contain a shared amino acid sequence not present in the wild type EGFR ( Figure  3 ). The joining of exons 1 and 8 in these two mutants creates a novel epitope with a glycine residue at the junction of the two exons, as has been noted previously (Humphrey et al., 1991) . EGFRvIII/D12 ± 13 has a second novel epitope due to the joining of exons 11 and 14 with preservation of a histidine residue at this junction. Similarly, the 180-kDa, tandem duplication mutant (EGFR.TDM/2 ± 7) contains a unique amino acid sequence due to joining of the 3'-end of exon 7 Figure 1 Western blot of human malignant glioma lysates probed with anti-EGFR antibody. Lysates were prepared as previously described (Ciesielski and Fenstermaker, 2000) and total protein was measured using the bicinchoninic acid method (Sigma). Proteins were resolved on 5% SDS ± PAGE, electroblotted onto Nytran membranes (Schleicher and Schuell) and then probed with anti-EGFR antibody 1005 (Santa-Cruz). Speci®c binding was detected by alkaline phosphatase-conjugated secondary antibodies and Immun-STAR chemiluminescent substrate (Bio-Rad). Samples include proteins from A-431 carcinoma cells for size comparison and several malignant glioma (glioblastoma multiforme) samples with the 5'-end of exon 2. This epitope is distinct from that present in EGFRvIII and introduces a unique leucine residue at that junction (Figure 3) .
We transfected U87 human glioma cells with expression vectors containing the cDNA of wild type EGFR, EGFRvIII, EGFRvIII/D12 ± 13 or EGFR.TDM/2 ± 7 under the control of a viral (MMLV) promoter. Both endogenous EGFR ( Figure  4e ) and wild type EGFR (Figure 4b ) were rapidly downregulated following stimulation with ligand. In contrast, levels of EGFRvIII were not reduced signi®cantly by ligand (Figure 4c ). This is consistent with the known impairment in both ligand binding and downregulation of EGFRvIII (Chu et al., 1997; Huang et al., 1997) . Similarly, the tandem mutant EGFR.TDM/2 ± 7 was poorly downregulated, despite potent induction of mutant receptor phosphorylation by ligand (Figures 4a and 5a) . Like EGFRvIII and EGFR.TDM/2 ± 7, the double deletion mutant EGFRvIII/D12 ± 13 was poorly downregulated by ligand (Figure 4d ).
U87 cells express some endogenous wild type EGFR (Figure 4e ), which is phosphorylated in response to ligand (Figure 5e ). Phosphorylation of the wild type receptor was also rapidly and strongly induced after addition of ligand to cultured U87 cells that had been transfected with the wild type EGFR cDNA to enhance expression (Figure 5b ). EGFRvIII exhibited constitutive basal phosphorylation without detectable induction by ligand (Figure 5c ). EGFR.TDM/2 ± 7 also displayed constitutive basal phosphorylation ( Figure  5a ). In contrast to EGFRvIII, however, addition of EGF to culture medium strongly induced phosphorylation of the tandem duplication mutant. Thus, despite Figure 2 Representative RT ± PCR reactions using seven pairs of ODN with cDNA template mixes from A-431 carcinoma cells and RPG-28. Gliomas obtained at surgery were¯ash-frozen in liquid nitrogen. Total cellular RNA was isolated with RNeasy silica resin columns (Qiagen) according to the manufacturer's instructions. Reverse transcription and RCR reactions were performed as previously described (Ciesielski and Fenstermaker, 2000) . PCR fragments were generated using a mixture of 1.5 units Taq polymerase (Life Technologies) and 0.075 units Pfu polymerase (Stratagene). Reactions were incubated in a thermal cycler (Perkin Elmer) at 948630 s, 608630 s, and 72866 min, for 30 cycles. Reaction products were resolved on 1% agarose and 6% polyacrylamide gels. ODN pairs and resulting PCR products correspond to: (a) the CAIN domain and its junction with the TK region (+3116 to +3380); (b) the 5'-end of the coding region and exon 2 (lanes 1 ± 2; +187 to +311); exon 1 and exon 2 (lanes 3 ± 4; +245 to +311); and the 5'-and 3'-ends of exon 3 (lanes 5 ± 6; +497 to +576); (c) exon 7 and exon 8 (+1029 to +1113); (d) the 5'-end of the coding region and exon 8 (+187 to +1113); and (e) the entire coding region (+187 to +3819). (f) Wild type EGFR cDNA structure with functional domains indicated. The numbering system for ODN is derived from the published cDNA sequence with numbers corresponding to the 5'-end of each ODN relative to the coding strand (Ullrich et al., 1984) . Lines with arrows indicate expected wild type fragment sizes from the PCR reactions in a ± e respectively signi®cant alteration in the extracellular portion of the molecule, EGFR.TDM/2 ± 7 appears to be capable of activation by ligand. In contrast to the other mutants, EGFRvIII/D12 ± 13 was not phosphorylated either constitutively or in response to ligand, even though the intracellular region of that molecule was shown to be unaltered using DNA sequence analysis (Figure 5d ).
EGFR forms of high molecular weight have been reported previously in human glioma cell lines and a number of structural and functional characteristics of these proteins have been described (Panneerselvam et al., 1995; Steck et al., 1988; Fenstermaker et al., 1998; Ciesielski and Fenstermaker, 2000; Frederick et al., 2000) . We, and others have previously reported the genetic structure of two of these EGFR mutants found in human glioma cell lines and biopsy samples (Fenstermaker et al., 1998; Ciesielski and Fenstermaker, 2000; Frederick et al., 2000) . These mutants are 185-kDa and 190-kDa EGFR species found in association with mRNA transcripts containing tandem duplication of exons 18 ± 25 and 18 ± 26, respectively. These tandem duplication mutants contain either partial or complete duplication of the TK and CAIN domains. Both TK/CAIN mutants identi®ed to date have constitutively active tyrosine kinase function with impaired ligand binding and receptor downregulation (Ciesielski and Fenstermaker, 2000) . The mutants arise from recombination between introns¯anking the duplicated region.
The current report describes a dierent tandem duplication mutant involving exons 2 ± 7. In this tumor, EGFR.TDM/2 ± 7 was co-expressed with the more common EGFRvIII deletion mutant. This particular TDM appears to be closely related to EGFRvIII with duplication of the same exons that are deleted in EGFRvIII. Simultaneous expression of both tandem duplication and deletion mutants in a given tumor suggests that the mechanisms underlying both deletion and tandem duplication might be fundamentally related. The presence of a double deletion mutant (EGFRvIII/D12 ± 13) in the glioma reported here and those observed by others (Frederick et al., 2000) suggests that other types of EGFR deletion mutations may arise by a similar process as that which produces EGFRvIII. Moreover, these observations in a tumor Figure 3 Coding region structure of wild type EGFR, EGFRvIII, EGFRvIII/D12 ± 13 and EGFR.TDM/2 ± 7 transcripts with key exon boundaries and corresponding functional domains. PCR fragments were eluted from gels ( Figure 2 ) using Qiaquick gel columns (Qiagen). Isolated fragments were tailed with dATP using Taq polymerase and were ligated into the pCRII-Topo 1 (Invitrogen). DNA sequencing was performed using automated methods. Partial nucleotide and predicted amino acid sequences of wild type and mutant molecules at key exon junctions are shown: bracketed amino acids arise from the interexon codons. Underlined, bracketed amino acids are unique to the mutants 535* CACA ± GTT CACT ± GTG Numbers represent the distance in nucleotides of the 5'-end of each heptamer motif from the 5'-end of each respective intron, except for (*), which indicates distance from 3'-end of intron biopsy specimen provide strong evidence that tandem duplication of EGFR sequences is not an artifact of cell culture. This report provides a single example of the EGFR.TDM/2 ± 7. The frequency of this TDM and others reported to date will need to be established by examining a large number of additional tumors. The tandem duplication mutant identi®ed in A-172 human glioma cells is the product of recombination between introns that¯ank the duplicated region of the EGFR gene. Analysis of introns in A-172 cells revealed the presence of a chimeric intron containing portions of both introns 17 and 26 (Fenstermaker et al., 1998) . A similar relationship exists in KE and A-1235 human glioma cells with chimeric introns formed as a result of recombination between introns 17 and 25 (Ciesielski and Fenstermaker, 2000) . The in-frame arrangement of exons in EGFR.TDM/2 ± 7, EGFR.TDM/18 ± 26, EGFR.TDM/18 ± 25, EGFRvIII, EGFRvIII/D12 ± 13 and the other EGFR deletion mutants reported to date suggests that related mechanisms involving intron recombination may give rise to both deletion and tandem duplication. In addition, recombination leading to either DM or TDM could involve similar proteins and DNA motifs in¯anking introns.
In tumor cells, DNA rearrangement occurs frequently leading to translocation, inversion and deletion. As a result, speci®c gene rearrangements are associated with the development of particular tumor types (LeBeau and Rowley, 1986) . One example of this is Burkitt's lymphoma in which t(8;14) translocation results from aberrant V(D)J recombination which brings the IgH transcriptional enhancer into proximity with the c-myc gene. Similarly, the interchromosomal translocation t(14;18) present in 90% of follicular lymphomas produces aberrant activation of the BCL2 gene (Wyatt et al., 1992) . Thus, the inappropriate diversion of V(D)J rearrangement has been postulated to account for such DNA translocations in lymphoid malignancies and could possibly constitute a source of oncogenic activation in solid tumors as well (Hiom et al., 1998) .
We have previously sequenced introns 17, 25 and 26 and the chimeric introns associated with the respective tandem duplications. Each of these introns contains two or more heptameric sequences that are homologous to recombination signal sequences (RSS) that have been implicated in V(D)J rearrangement of the T cell receptor genes (Ciesielski and Fenstermaker, 2000) . We have also identi®ed potential RSS heptamers in introns 7 and 11 suggesting that such sequences might Figure 4 Western blots of EGFR proteins immunoprecipitated from transfected U87 glioma cells. Full-length cDNA from RT ± PCR products were cloned into the pLXIN expression vector (Clontech). Each cDNA was cut at engineered terminal 5'-NotI and 3'-XhoI sites and introduced into the HpaI and XhoI sites of pLXIN. U87 cells were transfected with plasmid DNA using LipofectAMINE TM (Gibco) according to the manufacturers instructions. Cells were selected with G418 (400 mg/ml) and resistant clones were lifted with cloning discs (Bel-Art Products). U87 transfectants were maintained in de®ned medium (Optimem) and treated with (+) or without (7) EGF (100 ng/ml) for the indicated times. EGFR forms were immunoprecipitated from tumor cell lysates with antibody 1005 (Santa Cruz) using a standard amounts of protein extract (200 mg) from each cell line and applied to 5% SDS-polyacrylamide gels. After electroblotting onto Nytran membranes (Schleicher and Schuell), anti-EGFR antibody 1005 (Santa-Cruz) was used for Western blot detection of EGFR forms as reported previously (Fenstermaker et al., 1998) Figure 5 Western blots of EGFR phosphoproteins immunoprecipitated from transfected U87 glioma cells. Cell lines described in Figure 4 were maintained in de®ned medium (Optimem) and treated with (+) or without (7) EGF (100 ng/ml) for the indicated times. Immunoprecipitations were performed with equal amounts of protein extract (200 mg) from each cell line using antiphosphotyrosine PY99 antibody (Santa Cruz) for 18 h, followed by incubation with protein-A agarose beads (Ciesielski and Fenstermaker, 2000) . Immunoprecipitates were electroblotted onto Nytran membranes and probed with anti-EGFR antibody 1005 (Santa-Cruz) overnight at 48C. Speci®c binding was detected as described above also be involved in EGFR deletion mutations (Table  1) . A RSS heptamer sequence has also been identi®ed in a breakpoint cluster region in intron 2 of the retinoic acid receptor alpha (RARA) gene which is involved in the 15;17 chromosomal translocation of acute promyelocytic leukemia (Tashiro et al., 1994) . V(D)J recombination in lymphocytes is mediated by recombination-activating gene (RAG) products (Bailin et al., 1999 ). An interaction of RAG proteins with transposable elements in the development of lymphoid malignancies has been postulated (Hiom et al., 1998) . RAG1 expression has also been identi®ed in the central nervous system and in brain tumors as well (Chun et al., 1991) . RAG2 has been identi®ed in the brain in some studies, but not in others. This leaves the functional signi®cance of these two proteins and their possible role in gene recombination in the brain uncertain (Aoki et al., 1991; Chun et al., 1991) . Nevertheless, the occurrence of recombination between EGFR introns containing multiple copies of RSS heptamers raises the possibility that RAG proteins and RSS could promote the development of DM or TDM in EGFR. Thus, it is tempting to speculate that the molecular processes involved in immunological diversi®cation might be diverted to produce oncogenic growth factor receptor mutants in human gliomas.
Overexpression of TGFa or EGF may lead to cellular proliferation and maintenance of a transformed state by way of autocrine stimulation of the EGFR (Blasband et al., 1990; Maruno et al., 1991) . Liganddependent cellular transformation has been reported to occur in ®broblasts and immortalized murine astrocytes following high-level expression of the wild type receptor (Di Fiore et al., 1987; Frisa et al., 1996) . Thus, in the presence of other critical genetic alterations, ligand-dependent glial cell transformation may occur via overexpression of an otherwise normally functioning EGFR.EGFR.TDM/2 ± 7 exhibits enhanced basal autophosphorylation. Despite signi®cant structural change in the extracellular region of the molecule, it remains capable of binding to and being activated by ligand. Thus, EGFR.TDM/2 ± 7 might promote cellular transformation by both autocrine stimulation and constitutive activation of the mutant receptor. Similar results have been observed for both TK/CAIN tandem duplication mutants, although such mutants are not induced by ligand to the same extent as EGFR.TDM/ 2 ± 7 (Ciesielski and Fenstermaker, 2000) .
It has been suggested that in addition to unregulated tyrosine kinase activation, EGFRvIII may transduce its oncogenic signal by way of inecient receptor downregulation (Chu et al., 1997; Huang et al., 1997) . Thus, along with constitutive autophosphorylation, oncogenic activation by EGFRvIII may result from prolonged cell-surface receptor half-life (Wells et al., 1990) . Our results are consistent with both of these potential mechanisms of oncogenic activation for EGFRvIII. Similarly, EGFR.TDM/2 ± 7 may be unable to attenuate mitogenic signaling via ecient ligand-mediated receptor internalization. Thus, EGFR.TDM/2 ± 7 could promote oncogenesis by way of both constitutive and ligand-stimulated receptor activation, as well as by impaired receptor downregulation.
EGFRvIII may activate a dierent complement of substrates than the wild type EGFR (Moscatello et al., 1996; Chu et al., 1997; Montgomery et al., 1995) . Consequently, co-expression of wild type EGFR and EGFRvIII, or tandem duplication mutant EGFR forms like EGFR.TDM/2 ± 7, could help to maintain a transformed state by simultaneous activation of collateral signaling pathways. In this manner, coexpression of both wild type and mutant forms of the EGFR could produce an additive or synergistic eect on tumor growth or cellular transformation. This is of potential signi®cance since most gliomas with EGFRvIII or TDM expression produce wild type EGFR as well (our unpublished observations). Thus, co-expression of more than one EGFR species could promote tumor growth by a variety of dierent mechanisms.
Note added in proof
Recently, the entire 123-kb sequence of EGFR intron 1 became available for study through the Human Genome Project (GenBank). Intron 1 contains 35 copies of the V(D)J heptamer, including both CACAGTG and CACTGTG motifs, and three copies of the V(D)J nonamer (ACAAAAACC).
